Skip to main content
AMAN logo

AMAN · Amanat Acquisition Corp. · Documents

Track AMAN — free
$10.10 +0.03 (+0.30%) At close · Nov 19
Market Cap
$97.72M
Shares
9.68M
Volume · Nov 19 51.73K Avg daily vol (3M) 63.59K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Quarterly report New FY2026 Q3 Net loss $1.48M 10-Q filed Nov 13, 2026
2026
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Corxel combination expected to close in first half of 2027

Amanat Acquisition Corp. agreed to combine with Corxel Pharmaceuticals, with closing expected in the first half of 2027. Management reported a $1,510,880 net loss from January 13, 2026 through September 30, 2026 and substantial doubt about its ability to continue as a going concern.

Net loss $1.48M
Read from the MD&A section
5 source passages
References in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to Amanat Acquisition Corp. On October 25, 2026, we, Cairo Merger Sub, Inc., a Delaware corporation and our wholly-owned subsidiary (“Merger Sub”), Corxel Pharmaceuticals, Inc., a Delaware corporation (“Corxel”), and Corxel Pharmaceuticals Limited, a Cayman Islands exempted company and the sole stockholder of Corxel (“Parent”), entered into a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”). The business combination is expected to close in the first half of 2027, following the receipt of the requisite approvals of the Company’s shareholders and Corxel’s sole stockholder and the fulfillment of other customary closing conditions, including the expiration or termination of the applicable waiting period under the HSR Act. For the period from January 13, 2026 (inception) through September 30, 2026, we had net loss of $1,510,880, which consisted of formation, general and administrative costs of $2,376,371 and share-based compensation expense of $164,340, offset by change in fair value of over-allotment option liability of $58,600 and interest earned on investments held in the Trust Account of $971,231. These conditions raise substantial doubt about our ability to continue as a going concern. Open the document at this passage
Oct 26
Current report 8-K Events of Oct 25
Business combination with Corxel Pharmaceuticals at $200,000,000 equity value

On October 25, 2026, Amanat Acquisition Corp agreed to a business combination with Corxel Pharmaceuticals, based on an implied Corxel equity value of $200,000,000. The combination is expected to close in the first half of 2027, following approvals by Amanat's shareholders and Corxel's sole stockholder. The PIPE Financing carries aggregate purchase commitments of $300 million, subject to reduction mechanisms.

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure Read from the first part of this long document
5 source passages
On October 25, 2026, Amanat Acquisition Corp, a Cayman Islands exempted company which is based on an implied Corxel equity value of $200,000,000 The Business Combination is expected to close in the first half of 2027 following the receipt of the requisite approvals of AMAN’s shareholders and Corxel’s sole stockholder aggregate purchase commitments of $300 million, as adjusted for reduction mechanisms provided therein Open the document at this passage
May 27
Current report 8-K Events of May 20
Other events AI summary on its way
Showing 1–9 of 9 documents
Key facts CIK 2112457 CUSIP G0375M101 13F (30d) 24 filings 24 filers Visit website Investor relations